Advertisement
U.S. markets closed

Outlook Therapeutics, Inc. (OTLK)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
11.94+2.57 (+27.43%)
At close: 04:00PM EDT
12.33 +0.39 (+3.27%)
After hours: 07:42PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Commodity Channel Index

Commodity Channel Index

Previous Close9.37
Open9.39
Bid9.03 x 200
Ask11.97 x 100
Day's Range9.39 - 12.70
52 Week Range4.00 - 40.60
Volume1,543,665
Avg. Volume540,625
Market Cap257.717M
Beta (5Y Monthly)-0.00
PE Ratio (TTM)N/A
EPS (TTM)-4.00
Earnings DateMay 13, 2024 - May 17, 2024
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est40.20
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for OTLK

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Outlook Therapeutics, Inc.
    Daily – Vickers Top Insider Picks for 12/15/2022The Vickers Top Insider Picks is a daily report that utilizes a proprietary algorithm to identify 25 companies with compelling insider purchase histories based on transactions over the past three months.
    Rating
    Fair Value
    Economic Moat
    last yearArgus Research
View more
  • GlobeNewswire

    Outlook Therapeutics® Receives European Union Positive CHMP Opinion for ONS-5010 as a Treatment for Wet AMD

    Positive opinion serves as a basis for final decision for potential authorization from the European Commission (EC), expected within 67 days ISELIN, N.J., March 22, 2024 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company working to achieve the first approval for an ophthalmic formulation of bevacizumab for the treatment of retinal diseases in the US and the EU, today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European M

  • GlobeNewswire

    Outlook Therapeutics® Announces Closing of Private Placement of up to $159 Million

    ISELIN, N.J., March 18, 2024 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company working to achieve the first approval for an ophthalmic formulation of bevacizumab for the treatment of retinal diseases in the US and the EU, today announced that it has closed its previously announced private placement, for upfront gross proceeds of approximately $60 million from the issuance and sale of shares of the Company’s common stock and accompanying warrants, before d

  • GlobeNewswire

    Outlook Therapeutics® Announces Effective Date for 1-for-20 Reverse Stock Split

    ISELIN, N.J., March 12, 2024 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK) (the “Company”), a biopharmaceutical company working to achieve FDA approval for the first ophthalmic formulation of bevacizumab for the treatment of retinal diseases, today announced that a 1-for-20 reverse stock split of its outstanding shares of common stock will be effective on March 14, 2024. The Company’s common stock will begin trading on a reverse stock split-adjusted basis at the opening of the ma